Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives.

Barroso-Sousa R, Silva DD, Alessi JV, Mano MS.

Ecancermedicalscience. 2016 Jan 7;10:609. eCollection 2016. Review.

2.

Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.

Asano Y, Kashiwagi S, Onoda N, Kurata K, Morisaki T, Noda S, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K.

Br J Cancer. 2016 Jan 12;114(1):14-20. doi: 10.1038/bjc.2015.434.

3.

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3.

4.

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.

Cao L, Yao GY, Liu MF, Chen LJ, Hu XL, Ye CS.

PLoS One. 2015 Dec 30;10(12):e0145442. doi: 10.1371/journal.pone.0145442. eCollection 2015.

5.

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT.

Oncologist. 2016 Jan;21(1):21-7. doi: 10.1634/theoncologist.2015-0101. Epub 2015 Dec 9.

PMID:
26659222
6.

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.

7.

Magnetic Resonance Imaging-Guided Breast Interventions: Role in Biopsy Targeting and Lumpectomies.

Gombos EC, Jagadeesan J, Richman DM, Kacher DF.

Magn Reson Imaging Clin N Am. 2015 Nov;23(4):547-61. doi: 10.1016/j.mric.2015.05.004. Epub 2015 Jul 8. Review.

PMID:
26499274
8.

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.

Advani P, Cornell L, Chumsri S, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2015 Sep 22;7:321-35. doi: 10.2147/BCTT.S90627. eCollection 2015. Review.

9.

Spirulina platensis Lacks Antitumor Effect against Solid Ehrlich Carcinoma in Female Mice.

Barakat W, Elshazly SM, Mahmoud AA.

Adv Pharmacol Sci. 2015;2015:132873. doi: 10.1155/2015/132873. Epub 2015 Aug 20.

10.

Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy.

Gómez R, Ossa CA, Montoya ME, Echeverri C, Ángel G, Ascuntar J, Borrero M, Gil M, Herrera S, Gutiérrez E, Herazo F, Jiménez A, Madrid J, Reyes PA, Zuluaga L, García H.

Ecancermedicalscience. 2015 Aug 6;9:562. doi: 10.3332/ecancer.2015.562. eCollection 2015.

11.

Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?

Charehbili A, Fontein DB, Kroep JR, Liefers GJ, Nortier JW, Velde CJ.

J Clin Med. 2013 Oct 16;2(4):188-200. doi: 10.3390/jcm2040188.

12.

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Ann Surg. 2015 Sep;262(3):434-9; discussion 438-9. doi: 10.1097/SLA.0000000000001417.

13.

Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.

An YY, Kim SH, Kang BJ, Lee AW.

J Korean Med Sci. 2015 Jun;30(6):808-15. doi: 10.3346/jkms.2015.30.6.808. Epub 2015 May 13. Erratum in: J Korean Med Sci. 2015 Dec;30(12):1924.

14.

Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.

Grassadonia A, Caporale M, Tinari N, Zilli M, DeTursi M, Gamucci T, Vici P, Natoli C.

J Cancer. 2015 May 12;6(6):575-82. doi: 10.7150/jca.11566. eCollection 2015. Review.

15.

DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.

Budach W, Matuschek C, Bölke E, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of German Society of Radiation Oncology (DEGRO).

Strahlenther Onkol. 2015 Aug;191(8):623-33. doi: 10.1007/s00066-015-0843-1. Epub 2015 May 12. Erratum in: Strahlenther Onkol. 2015 Aug;191(8):634. Wenz, Frederick [corrected to Wenz, Frederik].

16.

Treatment of early-stage HER2+ breast cancer-an evolving field.

Ferreira AR, Saini KS, Metzger-Filho O.

Ecancermedicalscience. 2015 Apr 16;9:523. doi: 10.3332/ecancer.2015.523. eCollection 2015. Review.

17.

Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.

Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M.

Croat Med J. 2015 Apr;56(2):128-38.

18.

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.

Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T.

BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7.

19.
20.

In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, Bonnetain F, Villanueva C.

Oncologist. 2015 Apr;20(4):344-50. doi: 10.1634/theoncologist.2014-0198. Epub 2015 Mar 20.

PMID:
25795632
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk